Bosh sahifaBLUE • NASDAQ
add
bluebird bio Inc
3,73 $
Dastlabki sotuv:(1,61%)-0,060
3,67 $
Yopilgan:14-mar, 7:00:00 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
3,86 $
Kunlik diapazon
3,67 $ - 3,85 $
Yillik diapazon
3,56 $ - 30,90 $
Bozor kapitalizatsiyasi
36,26 mln USD
Oʻrtacha hajm
449,09 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 10,61 mln | -14,36% |
Joriy xarajat | 62,94 mln | -36,60% |
Sof foyda | -60,81 mln | 30,29% |
Sof foyda marjasi | -573,01 | 18,60% |
Har bir ulushga tushum | -6,20 | 53,03% |
EBITDA | -48,76 mln | 44,96% |
Amaldagi soliq stavkasi | 0,10% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 70,65 mln | -59,46% |
Jami aktivlari | 465,06 mln | -24,21% |
Jami passivlari | 470,84 mln | 20,40% |
Umumiy kapital | -5,79 mln | — |
Tarqatilgan aksiyalar | 9,72 mln | — |
Narxi/balansdagi bahosi | -6,43 | — |
Aktivlardan daromad | -31,73% | — |
Kapitaldan daromad | -39,19% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -60,81 mln | 30,29% |
Operatsiyalardan naqd pul | -68,93 mln | -37,72% |
Sarmoyadan naqd pul | 466,00 ming | -99,25% |
Moliyadan naqd pul | -6,10 mln | 48,42% |
Naqd pulning sof oʻzgarishi | -74,57 mln | -38 339,49% |
Boʻsh pul | -48,44 mln | 22,76% |
Haqida
bluebird bio, Inc., based in Somerville, Massachusetts, is a biotechnology company that develops gene therapies for severe genetic disorders.
The company's only - in the European Union - approved drug is betibeglogene autotemcel, which treats transfusion-dependent beta thalassemia, a rare genetic blood disorder, and has been approved for use by the European Medicines Agency. The company has been criticized for the $1.8 million cost of the drug, which is the second most expensive drug in the world.
The company is developing LentiGlobin gene therapy for the treatment of sickle cell disease and cerebral adrenoleukodystrophy. It is also developing T cell product candidates to treat acute myeloid leukemia, Merkel-cell carcinoma, diffuse large B-cell lymphoma, and MAGEA4 solid tumors. Wikipedia
Tashkil etilgan
16-apr, 1992
Sayt
Xodimlar soni
282
